Table 3.
Survival information of patients with PD-L1 CPS ≥1 receiving immunotherapy.
| Treatment | Sample size | Treatment line | OS (m) | PFS (m) |
|---|---|---|---|---|
| Monotherapy | ||||
| Pembrolizumab1 | 256 | 1 | 10.6 (7.7–13.8) | 2 (1.5–2.8) |
| Toripalimab | 8 | 2 | 12.1 | 5.5 |
| Pembrolizumab2 | 196 | 2 | 9.1 (6.2–10.7) | 1.6 (1.5–2.7) |
| Nivolumab | 16 | ≥3 | 5.22 (2.79–9.36) | NA |
| Durvalumab | 9 | 2 | 2.9 (0.8–7) | 1.7 (0.8–1.8) |
| Avelumab3 | 46 | ≥2 | 4 (2.5–7.6) | 1.4 (1.4–2.8) |
| Avelumab4 | 74 | 1mn7 | 14.9 (8.7–17.3) | NA |
| Combined therapy | ||||
| Pembrolizumab+FC/XP5 | 257 | 1 | 12.5 (10.8–13.9) | 6.9 (5.7–7) |
| Pembrolizumab+SOX | 54 | 1 | NR | 9.4 (6.6–NR) |
| Pembrolizumab+FC/XP6 | 16 | 1 | 11.1 (5.4–22.3) | NA |
| Nivolumab+XELOX/FOLFOX | 641 | 1 | 14 (12.6–15) | 7.5 (7–8.4) |
NR, not reached; NA, not available; OS, overall survival; PFS, progression-free survival; FC, 5-FU plus cisplatin; XP, capecitabine plus cisplatin; SOX, S-1 plus oxaliplatin; XELOX, capecitabine plus oxaliplatin; FOLFOX, fluorouracil plus oxaliplatin.
1Results from KEYNOTE-062.
2Results from KEYNOTE-061.
5Results from KEYNOTE-062.
6Results from KEYNOTE-059 cohort 2.
71mn stands for first-line maintenance.